结肠镜联合粪便免疫化学检测可改善当前家族性结直肠癌结肠镜监测:一项模型研究
该建模研究使用ASCCA-FCRC模型模拟具有2倍和4倍结直肠癌风险的家族史人群,比较无监测、当前荷兰指南(45至75岁每5年结肠镜)及多种替代策略。最优策略为40至80岁每10年结肠镜、期间每2年粪便免疫化学检测(FIT),在2倍和4倍风险人群中均较当前监测提高质量调整生命年(QALYs)、减少结肠镜次数并节省成本。
要点
- 最优策略为40至80岁每10年结肠镜、期间每2年FIT,适用于2倍和4倍风险人群。
核心结论
- FIT可能在家族性结直肠癌监测中发挥重要作用。
- 与当前家族性结直肠癌监测相比,40至80岁每10年结肠镜联合期间每2年FIT可增加QALYs、减少结肠镜负担并降低成本。
- 当前监测未处于成本效果前沿的(近)效率区域。
研究设计与样本
- 使用腺瘤与锯齿状通路至结直肠癌(ASCCA)-家族性结直肠癌模型模拟结直肠癌发展。
- 模拟对象为有结直肠癌家族史、结直肠癌风险为一般人群2倍和4倍的个体。
- 模拟策略包括无监测、当前荷兰指南(45至75岁每5年结肠镜)及3组替代策略:结肠镜监测、结肠镜联合FIT监测、基于FIT的监测。
- 每组替代策略包含年龄范围和检测间隔不同的多种策略。
- 最优策略定义为满足以下所有标准的最高QALYs策略:处于成本效果前沿的(近)效率区域并与当前监测比较;效果非劣;结肠镜负担无实质性增加;且不更昂贵。
主要发现
- 最优策略为40至80岁每10年结肠镜、结肠镜检查之间每2年FIT,对2倍和4倍风险人群均适用。
- 当前监测未处于(近)效率区域。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The authors assessed whether familial colorectal cancer (FCRC) surveillance in individuals without hereditary CRC can be optimized METHODS: The Adenoma and Serrated Pathway to Colorectal Cancer (ASCCA)-FCRC model simulates CRC development in individuals with a family history of CRC at 2-fold and 4-fold increased CRC risk compared with the general population. The authors simulated a strategy without surveillance, the current Dutch guideline (5-yearly colonoscopy between ages 45 and 75 years), and the following 3 sets of alternative strategies: colonoscopy surveillance, surveillance combining colonoscopy and fecal immunochemical testing (FIT), and FIT-based surveillance. Each set included a range of strategies differing in age range and test interval. The optimal strategy was defined as the strategy with highest quality-adjusted life-years (QALYs) satisfying all of the following criteria: in the (near-)efficiency area of the cost-effectiveness frontier and compared with current surveillance; noninferior effectiveness; no substantial increase in colonoscopy burden; and not more expensive. RESULTS: The optimal strategy was 10-yearly colonoscopy with 2-yearly FIT between colonoscopies from ages 40 to 80 years for both 2-fold and 4-fold increased CRC risk. At 2-fold risk, this strategy prevented 0.8 more CRC deaths, gained 15.8 more QALYs at 731 fewer colonoscopies, and saved €98,000 over the lifetime of 1000 individuals compared with current surveillance. At 4-fold risk, figures were 2.1 more CRC deaths prevented, 37.0 more QALYs gained at 567 fewer colonoscopies, and €127,000 lower costs. Current surveillance was not (near-)efficient. CONCLUSIONS: FIT could play an important role in FCRC surveillance. Surveillance with 10-yearly colonoscopy and 2-yearly FIT between colonoscopies from ages 40 to 80 years increased QALYs and reduced colonoscopy burden and costs compared with current FCRC surveillance.
引用
- van Wifferen F, Greuter MJE, van Leerdam ME, et al. Combining Colonoscopy With Fecal Immunochemical Test Can Improve Current Familial Colorectal Cancer Colonoscopy Surveillance: A Modelling Study. Gastroenterology. 2024. PMID: 39214503. doi:10.1053/j.gastro.2024.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。